PortalPublikationenConfirmation of the reduction of hormone replacement therapy...

Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variant

Standard

Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variant. / Obazee, Ofure; Justenhoven, Christina; Winter, Stefan; Chang-Claude, Jenny; Rudolph, Anja; Seibold, Petra; Flesch-Janys, Dieter; Hannelius, Ulf; Li, Jingmei; Humphreys, Keith; Hall, Per; Giles, Graham; Severi, Gianluca; Baglietto, Laura; Southey, Melissa; Rabstein, Sylvia; Harth, Volker; Lotz, Anne; Pesch, Beate; Brüning, Thomas; Baisch, Christian; Ko, Yon-Dschun; Hamann, Ute; Brauch, Hiltrud.

in: BREAST CANCER RES TR, Jahrgang 138, Nr. 2, 01.04.2013, S. 543-8.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Obazee, O, Justenhoven, C, Winter, S, Chang-Claude, J, Rudolph, A, Seibold, P, Flesch-Janys, D, Hannelius, U, Li, J, Humphreys, K, Hall, P, Giles, G, Severi, G, Baglietto, L, Southey, M, Rabstein, S, Harth, V, Lotz, A, Pesch, B, Brüning, T, Baisch, C, Ko, Y-D, Hamann, U & Brauch, H 2013, 'Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variant', BREAST CANCER RES TR, Jg. 138, Nr. 2, S. 543-8. https://doi.org/10.1007/s10549-013-2448-7

APA

Obazee, O., Justenhoven, C., Winter, S., Chang-Claude, J., Rudolph, A., Seibold, P., Flesch-Janys, D., Hannelius, U., Li, J., Humphreys, K., Hall, P., Giles, G., Severi, G., Baglietto, L., Southey, M., Rabstein, S., Harth, V., Lotz, A., Pesch, B., ... Brauch, H. (2013). Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variant. BREAST CANCER RES TR, 138(2), 543-8. https://doi.org/10.1007/s10549-013-2448-7

Vancouver

Obazee O, Justenhoven C, Winter S, Chang-Claude J, Rudolph A, Seibold P et al. Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variant. BREAST CANCER RES TR. 2013 Apr 1;138(2):543-8. https://doi.org/10.1007/s10549-013-2448-7

Bibtex

@article{904d26e684694d8692468043a7c6221f,
title = "Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variant",
abstract = "17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) plays an important role in the biosynthesis of 17β-estradiol. The current study aimed at confirming the reduced risk of breast cancer in carriers of the non-synonymous HSD17B1_937_A>G (rs605059) polymorphism who used any hormone replacement therapy (HRT) for 10 years or longer. We performed an independent association study using four breast cancer case-control studies from Australia, Germany, and Sweden. In all, 5,777 cases and 8,189 age-matched controls of European descent were genotyped by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and TaqMan. Risk estimates were calculated by interaction analysis and main effect analysis adjusted for age and study. Main effect analyses for women using any HRT for 10 years or longer (1,428 cases versus 1,724 controls) revealed a protective effect of the HSD17B1_937_G allele on breast cancer risk (OR 0.86, 95 % CI: 0.73-0.99; p = 0.048). Thus, our previous finding of a protective effect of the HSD17B1_937_G allele on HRT-associated breast cancer risk has now been confirmed both in independent large patient cohorts and a comprehensive pooled analysis supporting the hypothesis that a HSD17B1-mediated decreased conversion of estrone to the more potent 17β-estradiol may reduce the estrogenic effects, thereby reducing the risk of developing breast cancer during long-term HRT use.",
keywords = "Breast Neoplasms, Case-Control Studies, Estradiol Dehydrogenases, Estrogen Replacement Therapy, Female, Gene Frequency, Genetic Predisposition to Disease, Heterozygote, Humans, Polymorphism, Single Nucleotide, Postmenopause, Risk Factors",
author = "Ofure Obazee and Christina Justenhoven and Stefan Winter and Jenny Chang-Claude and Anja Rudolph and Petra Seibold and Dieter Flesch-Janys and Ulf Hannelius and Jingmei Li and Keith Humphreys and Per Hall and Graham Giles and Gianluca Severi and Laura Baglietto and Melissa Southey and Sylvia Rabstein and Volker Harth and Anne Lotz and Beate Pesch and Thomas Br{\"u}ning and Christian Baisch and Yon-Dschun Ko and Ute Hamann and Hiltrud Brauch",
year = "2013",
month = apr,
day = "1",
doi = "10.1007/s10549-013-2448-7",
language = "English",
volume = "138",
pages = "543--8",
journal = "BREAST CANCER RES TR",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

RIS

TY - JOUR

T1 - Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variant

AU - Obazee, Ofure

AU - Justenhoven, Christina

AU - Winter, Stefan

AU - Chang-Claude, Jenny

AU - Rudolph, Anja

AU - Seibold, Petra

AU - Flesch-Janys, Dieter

AU - Hannelius, Ulf

AU - Li, Jingmei

AU - Humphreys, Keith

AU - Hall, Per

AU - Giles, Graham

AU - Severi, Gianluca

AU - Baglietto, Laura

AU - Southey, Melissa

AU - Rabstein, Sylvia

AU - Harth, Volker

AU - Lotz, Anne

AU - Pesch, Beate

AU - Brüning, Thomas

AU - Baisch, Christian

AU - Ko, Yon-Dschun

AU - Hamann, Ute

AU - Brauch, Hiltrud

PY - 2013/4/1

Y1 - 2013/4/1

N2 - 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) plays an important role in the biosynthesis of 17β-estradiol. The current study aimed at confirming the reduced risk of breast cancer in carriers of the non-synonymous HSD17B1_937_A>G (rs605059) polymorphism who used any hormone replacement therapy (HRT) for 10 years or longer. We performed an independent association study using four breast cancer case-control studies from Australia, Germany, and Sweden. In all, 5,777 cases and 8,189 age-matched controls of European descent were genotyped by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and TaqMan. Risk estimates were calculated by interaction analysis and main effect analysis adjusted for age and study. Main effect analyses for women using any HRT for 10 years or longer (1,428 cases versus 1,724 controls) revealed a protective effect of the HSD17B1_937_G allele on breast cancer risk (OR 0.86, 95 % CI: 0.73-0.99; p = 0.048). Thus, our previous finding of a protective effect of the HSD17B1_937_G allele on HRT-associated breast cancer risk has now been confirmed both in independent large patient cohorts and a comprehensive pooled analysis supporting the hypothesis that a HSD17B1-mediated decreased conversion of estrone to the more potent 17β-estradiol may reduce the estrogenic effects, thereby reducing the risk of developing breast cancer during long-term HRT use.

AB - 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) plays an important role in the biosynthesis of 17β-estradiol. The current study aimed at confirming the reduced risk of breast cancer in carriers of the non-synonymous HSD17B1_937_A>G (rs605059) polymorphism who used any hormone replacement therapy (HRT) for 10 years or longer. We performed an independent association study using four breast cancer case-control studies from Australia, Germany, and Sweden. In all, 5,777 cases and 8,189 age-matched controls of European descent were genotyped by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and TaqMan. Risk estimates were calculated by interaction analysis and main effect analysis adjusted for age and study. Main effect analyses for women using any HRT for 10 years or longer (1,428 cases versus 1,724 controls) revealed a protective effect of the HSD17B1_937_G allele on breast cancer risk (OR 0.86, 95 % CI: 0.73-0.99; p = 0.048). Thus, our previous finding of a protective effect of the HSD17B1_937_G allele on HRT-associated breast cancer risk has now been confirmed both in independent large patient cohorts and a comprehensive pooled analysis supporting the hypothesis that a HSD17B1-mediated decreased conversion of estrone to the more potent 17β-estradiol may reduce the estrogenic effects, thereby reducing the risk of developing breast cancer during long-term HRT use.

KW - Breast Neoplasms

KW - Case-Control Studies

KW - Estradiol Dehydrogenases

KW - Estrogen Replacement Therapy

KW - Female

KW - Gene Frequency

KW - Genetic Predisposition to Disease

KW - Heterozygote

KW - Humans

KW - Polymorphism, Single Nucleotide

KW - Postmenopause

KW - Risk Factors

U2 - 10.1007/s10549-013-2448-7

DO - 10.1007/s10549-013-2448-7

M3 - SCORING: Journal article

C2 - 23430226

VL - 138

SP - 543

EP - 548

JO - BREAST CANCER RES TR

JF - BREAST CANCER RES TR

SN - 0167-6806

IS - 2

ER -